Amyloid status imputed from a multimodal classifier including structural MRI distinguishes progressors from nonprogressors in a mild Alzheimer's disease clinical trial cohort
Abstract
Mild‐Alzheimer's disease (AD) subjects without significant Aβ pathology represent a confounding finding for clinical trials because they may not progress clinically on the expected trajectory, adding variance into analyses where slowing of progression is being measured.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 21, 2016
- Source ID
- 10.1016/j.jalz.2016.03.009
Entities
People
- Adam J. Schwarz
- Duygu Tosun
- Eric Siemers
- Joyce Suhy
- Karen L. Sundell
- Michael W. Weiner
- Peng Yu
- The Alzheimer’s Disease Neuroimaging Initiative*
- Yun-fei Chen
Organizations
- AbbVie
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Eisai
- Eli Lilly and Company
- Foundation for the National Institutes of Health
- GE HealthCare
- Hoffmann-La Roche
- Innogenetics
- Laboratoires Servier
- Lundbeck Foundation
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense